Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation. (December 2017)

• Record Type: Journal Article
• Authors: Duvall, Melody G.; Bruggemann, Thayse R.; Levy, Bruce D.
• Is Part Of: Molecular aspects of medicine. Volume 58(2017)
• Page Start: 44
• Page End: 56
• Publication Date: 2017-12
• Subjects: Lipoxins -- Resolvins -- Protectins -- Maresins -- Catabasis -- Efferocytosis -- Lung -- Leukocytes -- Airway -- Mucosa; Pathology, Molecular -- Periodicals; Medicine -- Periodicals; Biochemistry -- Periodicals; Medicine -- Periodicals; Molecular Biology -- Periodicals; Pathologie moléculaire -- Périodiques; Médecine -- Périodiques; Electronic journals; 612.015
• DOI: 10.1016/j.mam.2017.04.003
• Languages: English
• ISSNs: 0098-2997

Abstract

Abstract: Bronchi are exposed daily to irritants, microbes and allergens as well as extremes of temperature and acid. The airway mucosal epithelium plays a pivotal role as a sentinel, releasing alarmins when danger is encountered. To maintain homeostasis, an elaborate counter-regulatory network of signals and cellular effector mechanisms are needed. Specialized pro-resolving mediators (SPMs) are chemical mediators that enact resolution programs in response to injury, infection or allergy. SPMs are enzymatically derived from essential polyunsaturated fatty acids with potent cell-type specific immunoresolvent properties. SPMs signal by engaging cell-based receptors to turn off acute inflammatory responses and restore tissue homeostasis. Several common lung diseases involving the airways, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF), are characterized by unresolved bronchial inflammation. In preclinical murine models of lung disease, SPMs carry potent bronchoprotective actions. Here, we review cellular and molecular effects for SPM-initiated catabasis in the lung and their human translation.